SCHEMBL21911575

SCHEMBL21911575

CCc1cccc2c1OCCC21CCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.40
PDK2 Q15119 2/20 0.34
MTNR1A P48039 2/20 0.33
GABRA1 P14867 2/20 0.32
GABRB2 P47870 2/20 0.32
THRB P10828 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
NOTUM Q6P988 1/20 0.31
CYP2D6 P10635 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
SIGMAR1 Q99720 2/20 0.31
EBP Q15125 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258177 0.94 HDAC4 (0.39) HDAC4PDK2MTNR1AGABRA1GABRB2
SCHEMBL24046301 0.86 HDAC4 (0.41) HDAC4PDK2GABRA1GABRB2THRB
SCHEMBL27190824 0.79 HDAC4 (0.38) HDAC4PDK2MTNR1AGABRA1GABRB2
SCHEMBL24258180 0.79 HDAC4 (0.40) HDAC4PDK2GABRA1GABRB2CYP2D6
SCHEMBL21845455 0.77
SCHEMBL24258176 0.76 HTR6 (0.33)
SCHEMBL21845436 0.75 GABRA1 (0.32) GABRA1GABRB2
SCHEMBL21845220 0.75 PTGS1 (0.33)
SCHEMBL21936758 0.75 PDK2 (0.33) PDK2
SCHEMBL24184947 0.72 PTGS1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022036297-A1 NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
US-11236097-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-20200102318-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236097-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, CACNA1A HDAC4 2359/4885PDK2 4535/4885MTNR1A 472/4885
US-20200102318-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SCN11A, SCN10A, CACNA1A HDAC4 2359/4885PDK2 4535/4885MTNR1A 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.